Severe Asthma: Where Do We Stand?
Severe asthma poses significant disease-related and economic burdens in the United States. Challenges in practice include how to define “severe asthma” for a given patient, knowing which are the right tests to perform and when, and having a better understanding of a patient’s asthma phenotype. Determining asthma phenotype is the foundation of precision medicine for this persistent, often difficult to treat disease. Without an understanding of a patient’s asthma phenotype, it is difficult to optimize treatment and gain ground on outcomes such as daily symptoms, exacerbations, and hospitalizations. It is also evident that determining when to start a biologic therapy or use bronchial thermoplasty in real-world practice may be unclear. In the absence of clear guidelines addressing these specific issues, an expert panel convened to develop a consensus on a definition for severe asthma as well as guiding principles for biomarker testing, and the use of newer biologics and bronchial thermoplasty in these patients. This webcast presents the expert panel’s consensus on guiding principles and other practical issues related to the treatment of severe asthma.
Practicing Allergists / Immunologists
After viewing the video recording, learners should be able to…
- Discuss current unmet medical needs in patients with severe asthma
- Describe asthma phenotypes and endotypes and evaluate the viability of routine biomarker testing for asthma subtypes in practice
- Outline updated therapeutic decision-making guidance for patients with severe asthma that is based on biomarkers and other patient disease characteristics
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity was supported by an independent educational grant from Boston Scientific.
Michael Blaiss, MD, FACAAI
Executive Medical Director
American College of Allergy, Asthma & Immunology
Clinical Professor of Pediatrics
Medical College of Georgia
Mario Castro, MD, MPH
Alan A. and Edith L. Wolff Professor
Pulmonary and Critical Care Medicine
Professor of Medicine,
Pediatrics, and Radiology
Washington University School of Medicine
St. Louis, Missouri
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance